US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy

Core Insights - The U.S. Food and Drug Administration (FDA) has granted national priority vouchers to Merck's cholesterol pill and cancer therapy, marking them as the latest additions to the fast-track program [1] Group 1: Company Developments - Merck's cholesterol pill and cancer therapy have received national priority vouchers from the FDA, which may expedite their development and approval process [1] Group 2: Industry Implications - The granting of national priority vouchers indicates a supportive regulatory environment for innovative therapies in the pharmaceutical industry, potentially leading to faster market access for new treatments [1]